Curated News
By: NewsRamp Editorial Staff
May 14, 2026

Dogwood Therapeutics Advances Non-Opioid Pain Treatments with Key Pipeline Progress

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Dogwood Therapeutics' Phase 2b Halneuron data expected fall 2026, offering potential first-mover advantage in non-opioid pain market.
  • Dogwood's pipeline includes Halneuron (NaV 1.7 inhibitor) and SP16 (LRP1 agonist) targeting chemotherapy-induced neuropathic pain through distinct mechanisms.
  • Dogwood's non-opioid treatments aim to reduce suffering from chemotherapy-induced pain and neuropathy, improving quality of life for cancer patients.
  • SP16, an LRP1 agonist, may repair nerve damage by increasing pAKT and pERK, offering a novel approach to neuropathy treatment.

Impact - Why it Matters

This news matters because it highlights progress in developing non-opioid alternatives for pain management, particularly for chemotherapy-induced neuropathy. With the opioid crisis ongoing, new treatments like Halneuron and SP16 offer hope for patients seeking effective pain relief without addiction risks. Dogwood's advancements could transform care for cancer survivors and chronic pain sufferers, potentially reducing reliance on opioids.

Summary

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced its first quarter 2026 financial results, highlighting significant pipeline progress. The company, focused on non-opioid pain and neuropathy treatments, reported enrollment of 164 patients in its Phase 2b study for Halneuron®, a NaV 1.7 inhibitor targeting chemotherapy-induced neuropathic pain (CINP), with top-line results expected in fall 2026. Additionally, SP16, an LRP1 agonist for chemotherapy-induced peripheral neuropathy (CIPPN), received FDA clearance to begin Phase 1b development, fully funded by the National Cancer Institute and conducted at the University of Virginia. CEO Greg Duncan emphasized a strong operational start, including a global development license for legacy antiviral assets.

Financially, the company reported a net loss of $5.0 million for Q1 2026, compared to $12.2 million in Q1 2025, driven by reduced loss on debt conversion. Cash on hand of $13.2 million provides runway into Q4 2026. Research and development expenses rose slightly to $2.7 million due to increased drug development costs for Halneuron®. The company also completed a financing of up to $26.9 million in January 2026, with $12.5 million received so far, to advance Halneuron® through Phase 2b.

Dogwood Therapeutics’ pipeline includes Halneuron®, which has FDA fast track designation for CINP, and SP16 IV, an LRP1 agonist with anti-inflammatory and tissue-repair properties. The company is backed by CK Life Sciences Int’l. For more details, visit www.dwtx.com. This news, reported via NOTICIAS NEWSWIRE, underscores Dogwood's commitment to addressing pain without opioids.

Source Statement

This curated news summary relied on content disributed by Noticias Newswire. Read the original source here, Dogwood Therapeutics Advances Non-Opioid Pain Treatments with Key Pipeline Progress

blockchain registration record for this content.